

## Shuwen Biotech gets PD-L1 Detection Kit validation in Clinical Trials

17 September 2018 | News

**Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs**



Shuwen Biotech is the first in China to launch a locally manufactured proprietary PD-L1 test kit, which can accurately determine the expression status of PD-L1 in tumor tissues, and to provide laboratory testing services for anti-PD-L1/PD-1 drug development.

Recently, the investigation of the safety, efficacy and molecular marker efficacy of Hengrui Medicine's anti-PD-1 drug, SHR1210, in the treatment of patients with advanced esophageal squamous cell carcinoma who failed conventional therapy was published in the March 2018 issue of *Clinical Cancer Research*, in which one of Shuwen Biotech's PD-L1 detection kits was used and clinical results showed that patients positive for PD-L1 (PD-L1 expression  $\geq$  5%) have a higher objective response rate.

Shuwen Biotech's PD-L1 kits and testing services have been used by leading pharmaceutical companies for dozens of clinical trials against PD-1 immunotherapeutics, contributing to the development of tumor immunotherapy drugs.

Shuwen Biotech's CAP-certified Shuwen Guanz Diagnostic Laboratories also successfully passed CAP's multi-site, multi-country proficiency testing for PD-L1 testing.